Check out today’s featured companies who have recently raised a round of funding, and be sure to check out the full list of past healthcare IT fundings.
VieCure Raises $43 Million to Help Democratize Access to the Highest Caliber Cancer Care in Community Practices
- Round Led by Legendary Business Icon Mitch Rales, Co-Founder of Danaher, One of the World’s Most Successful Companies, and Northpond Ventures
- Funds Will Accelerate the Expansion of VieCure’s AI Platform and its Growing Footprint of Community Oncology Clinics
- VieCure is Partnering with Mitch Rales’s Business-Building Firm, New Bearing, to Instill in VieCure World-Class Operational Capabilities Through the New Bearing Foundational Business System
VieCure, a leading provider of intelligent software platforms for oncology care, has raised $43 million in funding to accelerate its mission to democratize access to precision medicine in community cancer care practices.
The round was led by Mitch Rales, Co-Founder of Danaher, and Northpond Ventures, with significant participation from Durable Capital Partners, Socium Ventures – a venture firm backed by Cox Enterprises, and Sator Grove Holdings. Additionally, Mitch Rales and Howard “Skip” Burris III, M.D., a past president of the American Society of Clinical Oncology (ASCO), have joined the company’s Board of Directors.
Addressing the Growing Complexity of Cancer Care
Community oncology clinics in the U.S. treat more than 80% of cancer patients each year, yet they are increasingly overburdened by the rapidly expanding complexity of delivering care. As a result, the pace of adopting precision medicine protocols is lagging, putting both the financial stability of practices and patient outcomes at potential risk.
VieCure’s Halo Intelligence platform supports clinics in reducing these complexities by ensuring clinicians have real-time access to everything they need to deliver the right treatment to every patient. As an AI-powered clinical decision support and smart electronic medical record platform, Halo combines structured patient data, artificial intelligence, and workflow automation to enhance the speed and precision of clinical decision-making while reducing the operational barriers associated with delivering best-in-class care.
“This investment marks a pivotal moment in our mission to transform how cancer care is delivered to patients everywhere,” said Michael Power, CEO at VieCure…
Full release here, originally announced January 12th, 2026.
Avalon Healthcare Solutions Announces Strategic Investment to Accelerate the Future of Diagnostic Intelligence
Avalon Healthcare Solutions, a trusted partner for Diagnostic Intelligence across the payer ecosystem, today announced a new majority investment from WindRose Health Investors, with continued support from existing investor Francisco Partners. The transaction strengthens Avalon’s foundation for future innovation and growth.
Avalon supports more than 90 million members and serves over 30 national, regional, and community health plans through its proprietary Diagnostic Insights Platform, which powers its Benefit Management and Analytics solutions. Avalon’s patented real-time automated policy enforcement engine (APEA) processes over 18 million claims per month, ensuring evidence-based, precise, and cost-effective diagnostic care.
Driving the Next Era of Diagnostic Intelligence
Diagnostics inform 70% of medical decisions, making diagnostic data one of the most powerful — and historically underleveraged — assets in healthcare. Avalon has built the only technology platform solely dedicated to unlocking clinical and financial value from diagnostics at scale.
This new investment will allow Avalon to:
- Expand its Diagnostic Intelligence capabilities
- Accelerate improvements in predictive analytics and evidence-based policy automation
- Strengthen its Diagnostic Insights Platform
- Scale into new markets, including TPAs and Brokers serving self-funded employers starting in 2026
- Deliver even more quantifiable value to health plans, providers, and members
Commitment to Clients, Partners, and Employees
There will be no changes to operations, service delivery, SLAs, client teams, pricing, or provider relations as a result of the transaction. Avalon’s mission — To be the driving force that unlocks the full potential of diagnostic science — empowering healthcare payers and providers with proven solutions that enable personalized care and enhance patient outcomes remains unchanged and is further strengthened by this investment.
“Avalon is entering an exciting new chapter,” said Bill Kerr, MD, CEO at Avalon…
Full release here, originally announced January 15th, 2026.
No comments:
Post a Comment